KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Petmed Express (PETS) Current Deferred Revenue (2023 - 2025)

Petmed Express has reported Current Deferred Revenue over the past 3 years, most recently at $800000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 33.33% year-over-year to $800000.0; the TTM value through Dec 2025 reached $800000.0, down 33.33%, while the annual FY2025 figure was $2.1 million, 19.23% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $800000.0 at Petmed Express, down from $1.0 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $3.6 million in Q3 2023 and troughed at $800000.0 in Q4 2025.
  • A 3-year average of $2.0 million and a median of $2.1 million in 2024 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 60.89% in 2024 and later dropped 19.23% in 2025.
  • Year by year, Current Deferred Revenue stood at $3.1 million in 2023, then plummeted by 60.89% to $1.2 million in 2024, then crashed by 33.33% to $800000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for PETS at $800000.0 in Q4 2025, $1.0 million in Q3 2025, and $1.1 million in Q2 2025.